Table 6 Analysis of the prognostic factors

Age

  < 60 years

21

1

1

  ≥ 60 years

6

1.58

0.957–2.164

1.97

1.180–2.668

Menstrual status

 Premenopausal

9

 Postmenopausal

18

1.792

1.057–2.601

1.32

0.847–1.809

Primary tumor size (cm)

  < 2

15

1

1

 2–5

6

1.675

1.011–2.917

1.115

0.980–3.028

  ≥ 5

5

2.174

1.039–4.632

2.538

1.157–4.251

 Tumor involving chest wall

1

3.548

1.387–8.171

1.478

1.245–1.773

Number of axillary metastatic lymph nodes

 0

14

1

1

 1–3

8

1.726

0.962–2.928

1.971

1.939–3.752

  ≥ 4

5

2.279

1.062–3.373

1.960

1.017–3.758

ER/PR status

 Positive

18

1

1

 Negative

9

2.120

1.204–3.243

2.310

1.673–3.554

Her-2 status

 Positive

15

1

1

 Negative

12

1.490

1.245–1.783

1.971

1.193–3.255

Time to postoperative liver metastasis (months)

1

1

 24

16

  ≥ 24

11

1.971

1.073–3.578

0.561

0.327–0.965

Number of intrahepatic lesions (N)

 Single

5

1

1

 Multiple

22

1.630

1.074–3.383

1.67

1.243–2.255

Size of intrahepatic lesions (cm)

  < 3

3

1

1

  ≥ 3

24

1.524

0.448–2.171

1.822

1.028–3.339

Presence of extrahepatic metastasis

 Yes

16

1

1

 No

11

1.578

1.012–3.654

0.258

0.214–1.012

Was combination therapy adopted?

 Yes

18

1

1

 No

9

2.275

1.462–3.540

0.891

0.799–0.993